Macrogenics (MGNX) EBT (2012 - 2026)
Macrogenics (MGNX) posted quarterly EBT of -$38.9 million for Q1 2026, up 8.91% year-over-year from -$35.7 million in Q1 2025, and down 160.57% quarter-over-quarter from -$14.9 million in Q4 2025.
Macrogenics (MGNX) EBT (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported EBT for 15 consecutive years, with -$38.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 8.91% year-over-year to -$38.9 million; the TTM figure through Mar 2026 stood at -$73.2 million (down 29.39% YoY), while the FY2025 annual figure was -$75.3 million, down 14.04% from the prior year.
- EBT declined to -$38.9 million in Q1 2026 per MGNX's latest filing, from -$14.9 million in the prior quarter.
- Across five years, EBT topped out at $56.3 million in Q3 2024 and bottomed at -$100.2 million in Q1 2024.
- Historically, EBT has averaged -$31.2 million across 5 years, with a median of -$38.9 million in 2026.
- Annual changes were most pronounced in 2023 — EBT plunged 511.87% — and 2024, when it surged 258.61%.
- Macrogenics' EBT stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then surged by 70.67% to -$14.5 million in 2024, then dropped by 3.14% to -$14.9 million in 2025, then plunged by 160.57% to -$38.9 million in 2026.
- Business Quant data shows MGNX's EBT at -$38.9 million in Q1 2026, -$14.9 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -38.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.91 Mn |
| Dec 31, 2025 | -14.93 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.15 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -14.48 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -100.20 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -47.06 Mn |
| Mar 31, 2023 | -46.25 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -67.54 Mn |
| Dec 31, 2021 | -385.83 Mn |
| Sep 30, 2021 | -72.91 Mn |
| Jun 30, 2021 | -94.21 Mn |